TY - JOUR
T1 - Lumen-apposing metal stents (with videos)
AU - Prepared by: ASGE TECHNOLOGY COMMITTEE
AU - Law, Ryan J.
AU - Chandrasekhara, Vinay
AU - Bhatt, Amit
AU - Bucobo, Juan Carlos
AU - Copland, Andrew P.
AU - Krishnan, Kumar
AU - Kumta, Nikhil A.
AU - Pannala, Rahul
AU - Parsi, Mansour A.
AU - Rahimi, Erik F.
AU - Saumoy, Monica
AU - Trikudanathan, Guru
AU - Trindade, Arvind J.
AU - Yang, Julie
AU - Lichtenstein, David R.
N1 - Funding Information:
The following authors disclosed financial relationships: R. Law: Consultant for Olympus America Inc and Medtronic; travel compensation from Olympus America Inc; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. V. Chandrasekhara: Consultant for Covidien LP; advisory board for Interpace Diagnostics; shareholder in Nevakar, Inc; grant support from Cook Medical LLC; food and beverage compensation from Olympus America Inc and Boston Scientific Corporation. A. Bhatt: Consultant for Lumendi LLC; patent for a commercial device licensed to Medtronic; food and beverage compensation from Lumendi LLC, Covidien LP, Boston Scientific Corporation, Olympus America Inc, and Shionogi Inc. J. Bucobo: Consultant for Cook Medical LLC; travel compensation from Cook Medical LLC and Olympus Corporation of the Americas; food and beverage compensation from Cook Medical LLC, Olympus Corporation of the Americas, Boston Scientific Corporation, AbbVie, Inc, Janssen Biotech, Inc, Steris Corporation, Ferring Pharmaceuticals Inc, Takeda Pharmaceuticals USA, Inc, Endogastric Solutions, Inc, Merck Sharp & Dohme Corporation, Dova Pharmaceuticals, Pfizer Inc, and Allergan Inc. A. Copland: Education compensation from Salix Pharmaceauticals, Ltd. K. Krishnan: Consultant for Olympus Corporation of the Americas and Medtronic; has received travel compensation and food and beverage from Olympus Corporation of the Americas; has received food and beverage from Boston Scientific Corporation. N. Kumta: Consultant for Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc; travel compensation from Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc; food and beverage compensation from Boston Scientific Corporation, Gyrus ACMI, Inc, Olympus Corporation of the Americas, and Apollo Endosurgery US Inc, Fijufilm Medical Systems USA, Inc, Steris Corporation, ERBE USA Inc, Endogastric Solutions, and Conmed Corporation. R. Pannala: Consultant for HCL Technologies; travel compensation from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Apollo Endosurgery US, Inc; scientific advisory board for Nestle Health Sciences. M. Parsi: Travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas, Conmed Corporation, Salix Pharmaceuticals, AbbVie, Inc, Shionogi Inc, Shire North American Group Inc, and Boston Scientific Corporation. E. Rahimi: Food and beverage compensation from AbbVie, Inc, Boston Scientific Corporation, and Covidien LP. M. Saumoy: Food and beverage compensation from Boston Scientific Corporation, Ethicon US, LLC, Allergan Inc, and AbbVie, Inc. G. Trikudanathan: Consultant for Boston Scientific Corporation; travel compensation from Boston Scientific Corporation; food and beverage compensation from Boston Scientific Corporation and Cook Medical LLC. A. Trindade: Consultant for Olympus Corporation of the Americas, Pentax of America, Inc, and Gyrus ACMI, Inc; food and beverage compensation from Olympus Corporation of the Americas, Pentax of America, Inc, and Gyrus ACMI, Inc; travel compensation from Pentax of America, Inc, Gyrus ACMI, Inc, and Boston Scientific Corporation; research grant from NinePoint Medical, Inc. J. Yang: Consultant for Olympus Corporation of the Americas and Cook Medical LLC; travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas, Cook Medical LLC, US Endoscopy, Boston Scientific Corporation, Conmed Corporation, Salix Pharmaceuticals, and AbbVie, Inc. D. Lichtenstein: Consultant for Olympus Corporation of the Americas, Augmenix, Inc, and Boston Scientific Corporation; education compensation and travel compensation from Olympus Corporation of the Americas; food and beverage compensation from Olympus Corporation of the Americas and Boston Scientific Corporation.
Publisher Copyright:
© 2021 American Society for Gastrointestinal Endoscopy
PY - 2021/9
Y1 - 2021/9
N2 - Background and Aims: Lumen-apposing metal stents (LAMSs) are a novel class of devices that have expanded the spectrum of endoscopic GI interventions. LAMSs with their dumbbell configuration, short saddle length, and large inner luminal diameter provide favorable stent characteristics to facilitate anastomosis formation between the gut lumen and adjacent structures. Methods: The MEDLINE database was searched through April 2021 for articles related to LAMSs by using additional relevant keywords such as “walled-off pancreatic necrosis,” “pseudocysts,” “pancreatic fluid collection,” “cholecystitis,” “gastroenterostomy,” in addition to “endoscopic treatment” and “endoscopic management,” among others. Results: This technology review describes the full spectrum of LAMS designs and delivery systems, techniques for deployment, procedural outcomes, safety, training issues, and financial considerations. Conclusions: Although LAMSs were initially introduced for drainage of pancreatic pseudocysts and walled-off necrosis, the versatility of these devices has led to a variety of off-label uses including gallbladder drainage, enteric bypass with the creation of gastroenterostomies, and treatment of luminal GI strictures.
AB - Background and Aims: Lumen-apposing metal stents (LAMSs) are a novel class of devices that have expanded the spectrum of endoscopic GI interventions. LAMSs with their dumbbell configuration, short saddle length, and large inner luminal diameter provide favorable stent characteristics to facilitate anastomosis formation between the gut lumen and adjacent structures. Methods: The MEDLINE database was searched through April 2021 for articles related to LAMSs by using additional relevant keywords such as “walled-off pancreatic necrosis,” “pseudocysts,” “pancreatic fluid collection,” “cholecystitis,” “gastroenterostomy,” in addition to “endoscopic treatment” and “endoscopic management,” among others. Results: This technology review describes the full spectrum of LAMS designs and delivery systems, techniques for deployment, procedural outcomes, safety, training issues, and financial considerations. Conclusions: Although LAMSs were initially introduced for drainage of pancreatic pseudocysts and walled-off necrosis, the versatility of these devices has led to a variety of off-label uses including gallbladder drainage, enteric bypass with the creation of gastroenterostomies, and treatment of luminal GI strictures.
UR - http://www.scopus.com/inward/record.url?scp=85111326283&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2021.05.020
DO - 10.1016/j.gie.2021.05.020
M3 - Article
C2 - 34311975
AN - SCOPUS:85111326283
SN - 0016-5107
VL - 94
SP - 457
EP - 470
JO - Gastrointestinal Endoscopy
JF - Gastrointestinal Endoscopy
IS - 3
ER -